Abstract
In pancreatic adenocarcinoma, initial imaging is essential to better select patients for surgery. Recent literature analysis of F18-Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET) in pancreatic adenocarcinoma is summarized in the present article. Performances of FDG PET in the fields of lymph node involvement, metastatic involvement and therapeutic efficacy assessment are described for its correct use in pancreatic adenocarcinoma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
